5-Amino-1MQ 5mg
A 5mg small molecule NNMT inhibitor studied in cells and mice. Supplied for research, with no published human clinical trials.
View record and quotation
16 research recordsPreclinical Late stage Late stage Authorised product Preclinical Late stage Authorised product Authorised product Preclinical Late stage Early human Authorised product Preclinical Authorised product Authorised product Authorised product
Metabolic Research
Explore incretin, amylin and metabolic peptide research, including Retatrutide, Semaglutide and native signalling peptides. Records explain molecule identity, study context and available evidence.
Research materials only. Not for human or animal consumption.
Cagrilintide 10mg
A 10mg lyophilised synthetic amylin analogue studied in Phase 3 trials with semaglutide. Supplied in a single vial for research use only.
View record and quotationEloralintide
An investigational weekly amylin receptor agonist with Phase 1/2 weight management findings and a Phase 3 programme spanning obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis.
View record and quotationMazdutide 5mg
A 5mg lyophilised oxyntomodulin analogue acting on GLP-1 and glucagon receptors. Supplied for research, not as a licensed medicine.
View record and quotationMOTS-c 40mg
A 40mg lyophilised mitochondrial peptide studied mainly in mice and cell models for metabolism, insulin sensitivity and exercise capacity.
View record and quotationRetatrutide
An investigational triple hormone receptor agonist in Phase 3 trials spanning obesity, type 2 diabetes and obesity related conditions including sleep apnoea and knee osteoarthritis.
View record and quotationSemaglutide
A GLP-1 receptor agonist supported by major randomised programmes in type 2 diabetes, chronic weight management and cardiovascular outcomes; authorisation depends on the named finished product, formulation, dose and indication.
View record and quotationTirzepatide 50mg
A 50mg lyophilised synthetic peptide acting on GIP and glucagon like peptide 1 receptors. Supplied in a single vial for research, not as a licensed medicine.
View record and quotationArg(34)GLP-1 (7–37)
The unacylated item mainly appears as a research intermediate, comparator, or building block in GLP-1 analogue design.
Read research recordC-Peptide
Human use is mainly measurement for diabetes classification, endogenous insulin assessment, and beta cell function trials.
Read research recordCBL-514
An investigational small molecule injection studied in early Phase II/IIa programmes for localized abdominal subcutaneous fat and cellulite; it is not an authorised medicine and other development areas remain exploratory.
Read research recordExenatide Acetate
Extensive human research in type 2 diabetes includes randomized studies and extensions of defined drug products.
Read research recordGLP-1 (7–37)
It is primarily a native peptide research tool and physiologic reference.
Read research recordLixisenatide
Clinical research is primarily in type 2 diabetes.
Read research recordLixisenatide Acetate
It has phase III human research in type 2 diabetes, including add on studies with basal insulin and metformin.
Read research recordPramlintide Acetate
It has extensive human diabetes research as adjunct to insulin in type 1 and type 2 diabetes, with gastrointestinal adverse effects and clinically important hypoglycemia risk in the treatment setting.
Read research record